Q-omics provides the consensus-scored ZNF558 profile across patient tissues and cancer cell-line models. ZNF558 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZNF558 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, ZNF558 RNA expression shows 20,571 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, KIRC, and UVM as cancer lineages where ZNF558 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF558 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF558 survival associations across molecular data types. ZNF558 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF558 RNA expression–survival associations across cancer types. High ZNF558 expression shows unfavorable associations in KICH and LGG, but favorable associations in HNSC, BLCA, READ and UCS. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ZNF558 RNA expression.
This table summarizes ZNF558 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF558. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF558 shows higher tumor expression in KIRC, COAD, HNSC, BLCA, CHOL and LUSC. The KIRC box plot shows higher ZNF558 RNA expression in tumor versus normal tissue (log2 FC = +0.537, t-test p < 0.001).
This table shows molecular features associated with ZNF558 in patient tissues and cancer cell lines. In patient samples, ZNF558 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF558 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and UPPER_AERODIGESTIVE_TRACT.
